Travere Therapeutics, Inc.   Report issue

For profit Phase 2
Founded: San Diego CA United States (2011)

Organization Overview

First Clinical Trial
2020
NCT05562362
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Travere Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

sparsentan (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autoimmune Diseases (Phase 2)

Glomerulonephritis (Phase 2)

Glomerulonephritis, IGA (Phase 2)

Immune System Diseases (Phase 2)

Kidney Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 1